Om Megashree Pharmaceuticals Limited – Today (Chait 3) is the last day to apply for the Initial Public Offering (IPO) of Om Megashree Pharmaceuticals Limited, which has been open for issue and sale since Falgun 27.
The company has now issued an IPO for the general public after allocating shares for Nepalese employed abroad.
Table of Contents
The company had received permission to issue 1.8 million shares worth Rs 180 million, equivalent to 30 percent of its issued capital of Rs 600 million, through an IPO. Out of this, 180,000 shares worth Rs 18 million, equivalent to 10 percent, have already been issued and distributed to Nepalis employed abroad after obtaining labor approval from the relevant body of the Government of Nepal.
Similarly, the company has already distributed 54,000 units to company employees and 90,000 units to mutual funds. Now, in the second phase, the company has issued 1.476 million units of ordinary shares to the general public.
In the company’s IPO, applications will have to be submitted for a minimum of 10 shares, while applications can be submitted for a maximum of 10,000 shares. As of 5 pm on Saturday, Chaitra 2, 16,18,978 people have applied for 19,643,000 shares in the company’s shares.
The company’s share issuance and sale manager is Prabhu Capital Limited. Investors can apply through the C-ASBA system using the software ‘Mero Share’ online, developed by all ASBA member banks and financial institutions approved by the Securities and Exchange Board of Nepal and their designated branch offices, and CDS and Clearing Limited.
In its rating for the IPO issuance, Care Rating Nepal has assigned the company a CareNP Double B Minus Issuer Rating. This indicates that there is a moderate risk in the company’s ability to meet its obligations.
The total cost of the project is 1.266399 billion rupees. The company’s cost of expenditure so far is 975436 million rupees, while the remaining cost of expenditure is 29963 million rupees. The project’s normal investment payback period is 7.15 years, while the discounted investment payback period is 9.75 years.
Om Megashree Pharmaceuticals Limited : About company
About Om Megashree Pharmaceuticals Limited.
The health care system in Nepal has evolved at a very rapid rate, and in unprecedented ways especially after the Covid-19 pandemic. The increasing need for access to health care has increased the rate of production and availability of drugs on the home front. With a vision to be a global organization following cGMP standards and European norms,
Of Megashree Pharmaceuticals’ endeavor to develop and manufacture quality medicine and assist people to live healthier lives globally.
Om Megashree Pharmaceuticals is a Nepalese pharmaceutical firm which is established in the year 2017. It started its operation as a private limited but became a public limited company in July 2022.
Om Megashree Pharmaceuticals’ state-of-the-art manufacturing plant is located at Jugedi-29, Chitwan, Nepal with a total area of 22044 sq ft and is equipped with highly sophisticated and advanced instruments and machineries to produce and supply a wide range of therapeutic dosage forms for human and veterinary use.
Today the plant produces Cardio Diabetic, Neuropsychiatric and other groups of specialty drugs in the forms like but not limited to tablets, capsules, dry syrups, cream, ointments and eye/ear drops.
Read More ————————————> Click Here